WHO Advises Against Obesity Drugs for Young Children
Listen
Vocabulary
Article
The World Health Organization has issued new guidance recommending that children under ten should not receive obesity medications, including GLP-1 weight-loss injections like Mounjaro and Wegovy. Although most of these drugs lack approval for such young patients, some physicians prescribe them outside their licensed indications, and pharmaceutical companies are currently conducting trials on children as young as six. This recommendation reflects growing concern about introducing pharmaceutical interventions early in childhood without sufficient long-term evidence of safety and efficacy.
The Case for Lifestyle Approaches
WHO emphasizes that treatment for childhood obesity should prioritize healthy eating habits and physical activity rather than medical or surgical interventions. The organization acknowledges potential value in certain digital technologies, such as activity trackers and interactive games designed to encourage movement, though it notes the evidence base remains limited. This approach aligns with the principle that sustainable weight management in young children requires behavioral and environmental modifications rather than pharmaceutical dependency, particularly when alternatives remain viable.
The Broader Context
Globally, approximately 170 million children and adolescents meet clinical definitions of obesity, including 70 million aged five to nine. This age group has experienced alarming growth in obesity rates since 1990, increasing from two percent to eight percent. WHO officials express particular caution about initiating long-term pharmaceutical therapy in young children without clear evidence regarding treatment duration and potential transitions to dietary management later in life, acknowledging that this represents an evolving field requiring continued evaluation.
Discussion Questions
- Why might WHO be cautious about using weight-loss medications in children under ten when such drugs are available and tested by pharmaceutical companies?
- What challenges might arise if a child begins taking an obesity drug at age six and relies on it for years without knowing when or how to stop?
- How could activity trackers and interactive games serve as alternatives to medication, and what limitations might they have in addressing childhood obesity?
- The article notes that obesity rates in five- to nine-year-olds increased from two percent to eight percent since 1990. What factors might explain this significant rise?
- If a child's family makes changes to diet and exercise but does not see results, at what age and under what conditions might medication become appropriate according to WHO guidance?
Open the full interactive lesson with tap-to-hear on every word →